Home › Trial NCT02248012
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
- Trial IDNCT02248012
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorHaukeland University Hospital
- Enrollment38
- Start date2014-12
- ConditionsNeuroendocrine Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.